Our proprietary HLA-matched CTL and Tumors compliment and confirm data obtained from traditional allogenic studies in the early stages of drug development. These well characterized cells are used to screen drug candidate function and mechanism of action across multiple assay formats included 2D, 3D co-cultures and in vivo models.

Example screening studies using our HLA-matched cell across various assay formats include:

  • Cytotoxic T Lymphocyte (CTL) assays to measure effect of drug candidate on CTL lysis of matched tumor.

  • Ability of drug candidates to overcome immunosuppression and enhance CTL activity.

  • Combination studies with approved therapies.

  • Chemokines and Chemokine Receptors involved in CTL infiltration under 2D and 3D conditions.

We have extensive data sets on the use of our HLA-matched cells. Please contact us to learn more.

CTL and Tumor 001 was derived from a colon cancer patient. This HLA-matched pairing is PD-L1 sensitive.

CTL and Tumor 002 derived from a female colon cancer patient at time of surgery. This HLA-matched cell pairing is PD-1 sensitive.


CTL and Tumor 003 derived from a melanoma male Caucasian patient. This HLA-matched cell pairing is PD-1 and PD-L1 sensitive.

TIL and Tumor 004 derived from a Stage 4 melanoma patient (male). This TIL and tumor pairing is Keytruda (PD-1) resistant. We have characterization data and sub population composition of the TIL. Tumor cell line is well characterized.

Normal and Fresh Patient Samples

We can access healthy donor whole blood or PBMCs to isolate immune cell populations for evaluating mechanisms of action and functional analysis of drug candidates.

Through our collaborations with hospital partners and working with credible vendors, we implement stringent sample collection protocols to ensure lymphocytes and tumors are processed accordingly. We isolate lymphocyte populations and process tumor tissues for use across various assay platforms.  In addition, we have expertise to characterize (genomic and phenotypic) tumors.